KALINSKI PAWEL has a total of 15 patent applications. Its first patent ever was published in 2008. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and environmental technology are CHS PHARMA INC, AMPLIPHI BIOSCIENCES CORP and BIOMUNE.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 6 | |
#2 | WIPO (World Intellectual Property Organization) | 3 | |
#3 | Australia | 1 | |
#4 | Canada | 1 | |
#5 | China | 1 | |
#6 | EPO (European Patent Office) | 1 | |
#7 | Republic of Korea | 1 | |
#8 | Mexico | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Environmental technology | |
#4 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Microorganisms | |
#4 | Climate change adaptation technologies | |
#5 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Kalinski Pawel | 15 |
#2 | Muthuswamy Ravikumar | 10 |
#3 | Obermajer Natasa | 2 |
#4 | Obermajer Nataša | 1 |
Publication | Filing date | Title |
---|---|---|
WO2014138093A1 | Modulating th17 responses | |
US2014255358A1 | Generation of immunosuppressive myeloid cells using pge2 | |
AU2012287024A1 | Tumor selective chemokine modulation | |
US2009004157A1 | Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use |